Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | inositol monophosphatase 1 | 0.0036 | 0.2079 | 0.4662 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.0032 | 0.1707 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.1982 | 0.4427 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.2627 | 0.2501 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.2079 | 1 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0036 | 0.2079 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0115 | 1 | 1 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0696 | 0.1287 |
Brugia malayi | Bromodomain containing protein | 0.0037 | 0.221 | 0.1417 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0058 | 0.4266 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0068 | 0.5325 | 0.5245 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0016 | 0.0169 | 0.0366 |
Schistosoma mansoni | methyl-cpg binding protein mbd | 0.0016 | 0.0169 | 0.0366 |
Schistosoma mansoni | inositol monophosphatase | 0.0036 | 0.2079 | 0.4509 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0036 | 0.2079 | 0.5 |
Schistosoma mansoni | methyl-cpg binding protein mbd | 0.0016 | 0.0169 | 0.0366 |
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0036 | 0.2079 | 0.5 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0036 | 0.2079 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.2217 | 0.2083 |
Brugia malayi | Inositol-1 | 0.0036 | 0.2079 | 0.1273 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0058 | 0.4266 | 1 |
Schistosoma mansoni | zinc finger protein | 0.0019 | 0.0411 | 0.0891 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0115 | 1 | 1 |
Loa Loa (eye worm) | PHD-finger family protein | 0.002 | 0.0513 | 0.035 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.2444 | 0.2314 |
Brugia malayi | Bromodomain containing protein | 0.0072 | 0.5736 | 0.5302 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.2079 | 1 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0017 | 0.0227 | 0.006 |
Echinococcus multilocularis | zinc finger protein | 0.0019 | 0.0411 | 0.0592 |
Echinococcus multilocularis | inositol monophosphatase 1 | 0.0036 | 0.2079 | 0.4662 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0696 | 0.151 |
Loa Loa (eye worm) | inositol-1 | 0.0036 | 0.2079 | 0.1943 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0036 | 0.2079 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.1982 | 0.4427 |
Mycobacterium tuberculosis | Inositol-1-monophosphatase SuhB | 0.0032 | 0.1707 | 0.5 |
Echinococcus granulosus | zinc finger protein | 0.0019 | 0.0411 | 0.0592 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.2079 | 1 |
Schistosoma mansoni | bromodomain containing protein | 0.0061 | 0.461 | 1 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0513 | 0.1112 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0696 | 0.1287 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0016 | 0.0169 | 0.0366 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0036 | 0.2079 | 0.5 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.2079 | 1 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0036 | 0.2079 | 0.5 |
Schistosoma mansoni | inositol monophosphatase | 0.0036 | 0.2079 | 0.4509 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.